E.Y. de Brabander

De Brabander, E. Y., Leibold, N. K., van Amelsvoort, T., van Westrhenen, R., Alizadeh, B. Z., Cahn, W., de Haan, L., van der Pluijm, M., Simons, C. J. P., van Os, J., Veling, W., & Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2025). Sex and age effects on prevalence of CYP2C19 and CYP2D6 Phenoconversion risk over time in patients with psychosis. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 138, Article 111363. https://doi.org/10.1016/j.pnpbp.2025.111363

De Brabander, E. Y., Breddels, E., van Amelsvoort, T., van Westrhenen, R., & Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2024). Clinical effects of CYP2D6 phenoconversion in patients with psychosis. Journal of Psychopharmacology, 38(12), 1095-1110. https://doi.org/10.1177/02698811241278844

De Brabander, E. Y., van Amelsvoort, T., van Westrhenen, R., & Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2024). Unidentified CYP2D6 genotype does not affect pharmacological treatment for patients with first episode psychosis. Journal of Psychopharmacology, 38(12), 1111-1121. https://doi.org/10.1177/02698811241279022

de Brabander, E., Kleine Schaars, K., van Amelsvoort, T., Budde, M., Heilbronner, U., Young, A. H., Juruena, M., Vieta, E., Fares-Otero, N. E., Kas, M. J., Nöthen, M., Philipsen, A., Kilarski, L. L., Laatsch, J., Rossner, M. J., Wichert, S. P., Moldovan, R., Shomron, N., Schulze, T. G., ... PSY-PGx Consortium (2024). Influence of CYP2C19 and CYP2D6 on side effects of aripiprazole and risperidone: A systematic review. Journal of Psychiatric Research, 174, 137-152. https://doi.org/10.1016/j.jpsychires.2024.04.001